206 related articles for article (PubMed ID: 15846461)
1. Covariate detection in population pharmacokinetics using partially linear mixed effects models.
Bonate PL
Pharm Res; 2005 Apr; 22(4):541-9. PubMed ID: 15846461
[TBL] [Abstract][Full Text] [Related]
2. Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test.
Xu XS; Yuan M; Yang H; Feng Y; Xu J; Pinheiro J
AAPS J; 2017 Jan; 19(1):264-273. PubMed ID: 27761720
[TBL] [Abstract][Full Text] [Related]
3. A Modified Hybrid Wald's Approximation Method for Efficient Covariate Selection in Population Pharmacokinetic Analysis.
Zou Y; Tang F; Ng CM
AAPS J; 2021 Mar; 23(2):37. PubMed ID: 33660056
[TBL] [Abstract][Full Text] [Related]
4. Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.
Combes FP; Retout S; Frey N; Mentré F
CPT Pharmacometrics Syst Pharmacol; 2014 Apr; 3(4):e109. PubMed ID: 24717242
[TBL] [Abstract][Full Text] [Related]
5. The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.
Silber HE; Kjellsson MC; Karlsson MO
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):81-99. PubMed ID: 19219538
[TBL] [Abstract][Full Text] [Related]
6. Permutation-based variance component test in generalized linear mixed model with application to multilocus genetic association study.
Zeng P; Zhao Y; Li H; Wang T; Chen F
BMC Med Res Methodol; 2015 Apr; 15():37. PubMed ID: 25897803
[TBL] [Abstract][Full Text] [Related]
7. Effect of correlation on covariate selection in linear and nonlinear mixed effect models.
Bonate PL
Pharm Stat; 2017 Jan; 16(1):45-54. PubMed ID: 27580760
[TBL] [Abstract][Full Text] [Related]
8. Assessment of actual significance levels for covariate effects in NONMEM.
Wählby U; Jonsson EN; Karlsson MO
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):231-52. PubMed ID: 11468939
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.
Bertrand J; Comets E; Laffont CM; Chenel M; Mentré F
J Pharmacokinet Pharmacodyn; 2009 Aug; 36(4):317-39. PubMed ID: 19562469
[TBL] [Abstract][Full Text] [Related]
10. Assessment of type I error rates for the statistical sub-model in NONMEM.
Wählby U; Bouw MR; Jonsson EN; Karlsson MO
J Pharmacokinet Pharmacodyn; 2002 Jun; 29(3):251-69. PubMed ID: 12449498
[TBL] [Abstract][Full Text] [Related]
11. Likelihood ratio tests in rare variant detection for continuous phenotypes.
Zeng P; Zhao Y; Liu J; Liu L; Zhang L; Wang T; Huang S; Chen F
Ann Hum Genet; 2014 Sep; 78(5):320-32. PubMed ID: 25117149
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of flucytosine: comparison and validation of three models using STS, NPEM, and NONMEM.
Vermes A; Math t RA; van der Sijs IH; Dankert J; Guchelaar HJ
Ther Drug Monit; 2000 Dec; 22(6):676-87. PubMed ID: 11128235
[TBL] [Abstract][Full Text] [Related]
13. Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.
Goulooze SC; Krekels EHJ; Hankemeier T; Knibbe CAJ
AAPS J; 2018 Dec; 21(1):11. PubMed ID: 30565031
[TBL] [Abstract][Full Text] [Related]
14. Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences.
Gobburu JV; Lawrence J
Pharm Res; 2002 Jan; 19(1):92-8. PubMed ID: 11841044
[TBL] [Abstract][Full Text] [Related]
15. Evaluation by simulation of tests based on non-linear mixed-effects models in pharmacokinetic interaction and bioequivalence cross-over trials.
Panhard X; Mentré F
Stat Med; 2005 May; 24(10):1509-24. PubMed ID: 15761916
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic comparability between two populations using nonlinear mixed effect models: a Monte Carlo study.
Sahasrabudhe SA; Bonate PL
J Pharmacokinet Pharmacodyn; 2023 Jun; 50(3):189-201. PubMed ID: 36708443
[TBL] [Abstract][Full Text] [Related]
17. A reduction in between subject variability is not mandatory for selecting a new covariate.
Lagishetty CV; Vajjah P; Duffull SB
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):383-92. PubMed ID: 22767340
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the estimation and classification performance of NONMEM when applying mixture model for drug clearance.
Hui KH; Lam TN
CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1564-1577. PubMed ID: 34648691
[TBL] [Abstract][Full Text] [Related]
19. Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Panhard X; Taburet AM; Piketti C; Mentré F
Stat Med; 2007 Mar; 26(6):1268-84. PubMed ID: 16810714
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
